WHO Model Prescribing Information: Drugs Used in Skin Diseases
(1997; 132 pages) [French] [Spanish] View the PDF document
Table of Contents
View the documentPreface
View the documentIntroduction
Open this folder and view contentsParasitic infections
Open this folder and view contentsInsect and arachnid bites and stings
Open this folder and view contentsSuperficial fungal infections
Open this folder and view contentsSubcutaneous fungal infections
Open this folder and view contentsBacterial infections
Open this folder and view contentsViral infections
Open this folder and view contentsEczematous diseases
Open this folder and view contentsScaling diseases
Open this folder and view contentsPapulosquamous diseases
View the documentCutaneous reactions to drugs
Open this folder and view contentsPigmentary disorders
Open this folder and view contentsPremalignant lesions and malignant tumours
Open this folder and view contentsPhotodermatoses
Open this folder and view contentsBullous dermatoses
View the documentAlopecia areata
View the documentUrticaria
Open this folder and view contentsConditions common in children
View the documentAcne vulgaris
View the documentPruritus
View the documentTropical ulcers
Open this folder and view contentsAntimicrobial drugs
Close this folderAntifugal drugs
View the documentAmphotericin B
View the documentBenzoic acid + salicylic acid (Whitfield’s ointment)
View the documentClotrimazole
View the documentEconazole
View the documentFluconazole
View the documentFlucytosine
View the documentGriseofulvin
View the documentItraconazole
View the documentKetoconazole
View the documentMiconazole
View the documentNystatin
View the documentPotassium iodide
View the documentSelenium sulfide
View the documentSodium thiosulfate
View the documentTerbinafine
Open this folder and view contentsAntiseptic agents
Open this folder and view contentsKeratoplastic and keratolytic agents
Open this folder and view contentsScabicides and pediculicides
Open this folder and view contentsAnti-inflammatory and antipruritic drugs1
Open this folder and view contentsAntiallergics and drugs used in anaphylaxis
Open this folder and view contentsUltraviolet radiation-blocking agents (sunscreens)
Open this folder and view contentsMiscellaneous drugs
Open this folder and view contentsAnnex
View the documentSelected WHO Publications of Related Interest
View the documentBack cover
 

Terbinafine

Tablet, 125 mg Cream, 1%

General information

Terbinafine is an allylamine. It has a narrow spectrum of antifungal activity after oral administration but is effective against the common superficial pathogens when applied topically. It is well absorbed following topical application and penetrates the epidermis in high concentrations. It is largely metabolized in the liver.

Clinical information

Uses

Treatment of ringworm (tinea), candidosis and onychomycosis.

Dosage and administration

All doses are suitable for adults and children.

Ringworm (tinea) and candidosis:

A thin layer of cream should be applied once or twice daily for 1-2 weeks. Symptoms usually resolve rapidly (within 3-7 days in tinea pedis).

Resistant tinea corporis or tinea pedis:

250 mg orally daily for 1-2 weeks.

Onychomycosis:

250 mg orally daily for 6-12 weeks.

Contraindications

Severe hepatic impairment.

Precautions

Liver function should be assessed before and at regular intervals during treatment in patients with mild hepatic impairment or alcohol dependence.

Use in pregnancy

Safe use in pregnancy has not been established. The need for treatment must be determined by the condition of the mother.

Adverse effects

Nausea and headache are common. Transient loss of taste may occur after oral administration. Hepatic toxicity is very rare.

Storage

Tablets and cream should be stored in well-closed containers, protected from light.

 

to previous section
to next section
 
 
The WHO Essential Medicines and Health Products Information Portal was designed and is maintained by Human Info NGO. Last updated: December 1, 2019